230 related articles for article (PubMed ID: 32444660)
1. Surrogate endpoints for overall survival in randomised controlled trials of localised osteosarcoma: A meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Matsuda S; Itonaga I; Tsumura H
Sci Rep; 2020 May; 10(1):8573. PubMed ID: 32444660
[TBL] [Abstract][Full Text] [Related]
2. A meta-analytic evaluation of the correlation between event-free survival and overall survival in randomized controlled trials of newly diagnosed Ewing sarcoma.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2020 May; 20(1):379. PubMed ID: 32370741
[TBL] [Abstract][Full Text] [Related]
3. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
[TBL] [Abstract][Full Text] [Related]
4. Surrogacy analysis of intermediate end-points for overall survival in randomized controlled trials of rhabdomyosarcoma.
Kubota Y; Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
Sci Rep; 2022 Nov; 12(1):19381. PubMed ID: 36371419
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.
Tabone MD; Brugières L; Piperno-Neumann S; Selva MA; Marec-Bérard P; Pacquement H; Lervat C; Corradini N; Gentet JC; Couderc R; Chevance A; Mahier-Ait Oukhatar C; Entz-Werle N; Blay JY; Le Deley MC
BMC Cancer; 2017 Jun; 17(1):419. PubMed ID: 28619014
[TBL] [Abstract][Full Text] [Related]
6. Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.
Xie W; Regan MM; Buyse M; Halabi S; Kantoff PW; Sartor O; Soule H; Berry D; Clarke N; Collette L; D'Amico A; Lourenco RA; Dignam J; Eisenberger M; James N; Fizazi K; Gillessen S; Loriot Y; Mottet N; Parulekar W; Sandler H; Spratt DE; Sydes MR; Tombal B; Williams S; Sweeney CJ;
J Clin Oncol; 2020 Sep; 38(26):3032-3041. PubMed ID: 32552276
[TBL] [Abstract][Full Text] [Related]
7. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
Hua T; Gao Y; Zhang R; Wei Y; Chen F
BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
[TBL] [Abstract][Full Text] [Related]
8. Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis.
Gharzai LA; Jiang R; Wallington D; Jones G; Birer S; Jairath N; Jaworski EM; McFarlane MR; Mahal BA; Nguyen PL; Sandler H; Morgan TM; Reichert ZR; Alumkal JJ; Mehra R; Kishan AU; Fizazi K; Halabi S; Schaeffer EM; Feng FY; Elliott D; Dess RT; Jackson WC; Schipper MJ; Spratt DE
Lancet Oncol; 2021 Mar; 22(3):402-410. PubMed ID: 33662287
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of alkaline phosphatase and prognosis for osteosarcoma.
Hao H; Chen L; Huang D; Ge J; Qiu Y; Hao L
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 27349943
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma.
Liu H; Wang Y; Qi C; Xie T; Peng Z; Li J; Shen L; Zhang X
Front Oncol; 2022; 12():835389. PubMed ID: 35463354
[TBL] [Abstract][Full Text] [Related]
11. Disease-free survival is not a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: a systematic review of randomized trials.
Petrelli F; Tomasello G; Ghidini M; Lonati V; Passalacqua R; Barni S
HPB (Oxford); 2017 Nov; 19(11):944-950. PubMed ID: 28764887
[TBL] [Abstract][Full Text] [Related]
12. Correlation Between Early Time-to-Event Outcomes and Overall Survival in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Receiving Definitive Chemoradiation Therapy: Systematic Review and Meta-Analysis.
Black CM; Keeping S; Mojebi A; Ramakrishnan K; Chirovsky D; Upadhyay N; Maciel D; Ayers D
Front Oncol; 2022; 12():868490. PubMed ID: 35574411
[TBL] [Abstract][Full Text] [Related]
13. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
[TBL] [Abstract][Full Text] [Related]
14. Intermediate endpoints as surrogates for outcomes in cancer immunotherapy: a systematic review and meta-analysis of phase 3 trials.
Zhang Z; Pan Q; Lu M; Zhao B
EClinicalMedicine; 2023 Sep; 63():102156. PubMed ID: 37600482
[TBL] [Abstract][Full Text] [Related]
15. Impact of chemotherapy-induced necrosis on event-free and overall survival after preoperative MAP chemotherapy in patients with primary high-grade localized osteosarcoma.
Tsuda Y; Tsoi K; Parry MC; Stevenson JD; Fujiwara T; Sumathi V; Jeys LM
Bone Joint J; 2020 Jun; 102-B(6):795-803. PubMed ID: 32475245
[TBL] [Abstract][Full Text] [Related]
16. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
[TBL] [Abstract][Full Text] [Related]
17. Optimized Image-Based Surrogate Endpoints in Targeted Therapies for Glioblastoma: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ; Kim KW
Korean J Radiol; 2020 Apr; 21(4):471-482. PubMed ID: 32193895
[TBL] [Abstract][Full Text] [Related]
18. Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials.
Petrelli F; Barni S
Med Oncol; 2014 Jan; 31(1):776. PubMed ID: 24271313
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival as a surrogate for overall survival in neoadjuvant trials of gastroesophageal adenocarcinoma: Pooled analysis of individual patient data from randomised controlled trials.
Ronellenfitsch U; Jensen K; Seide S; Kieser M; Schwarzbach M; Slanger TE; Burmeister B; Kelsen D; Niedzwiecki D; Piessen G; Schuhmacher C; Urba S; van de Velde C; Ychou M; Hofheinz R; Lorenzen S
Eur J Cancer; 2019 Dec; 123():101-111. PubMed ID: 31678767
[TBL] [Abstract][Full Text] [Related]
20. A correlation analysis to assess event-free survival as a trial-level surrogate for overall survival in early breast cancer.
Gyawali B; D'Andrea E; Franklin JM; Kesselheim AS
EClinicalMedicine; 2021 Feb; 32():100730. PubMed ID: 33681740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
